Pharmacology of S21402 (RB105): A Dual Inhibitor of Neutral Endopeptidase and Angiotensin Converting Enzyme
Open Access
- 1 June 1996
- journal article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 14 (2) , 166-184
- https://doi.org/10.1111/j.1527-3466.1996.tb00225.x
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.Hypertension, 1993
- Role of neutral endopeptidase in the metabolism of endothelin.Hypertension, 1992
- In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats.Hypertension, 1992
- Increased vascular responsiveness to bradykinin in kidneys of spontaneously hypertensive rats. Effect of N omega-nitro-L-arginine.Hypertension, 1991
- Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.Journal of Clinical Investigation, 1990
- Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.Hypertension, 1990
- Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension.Hypertension, 1988
- Enalapril attenuates natriuresis of atrial natriuretic factor in humans.Hypertension, 1988
- Renal function curve--a key to understanding the pathogenesis of hypertension.Hypertension, 1987
- Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertensionLife Sciences, 1986